Welcome to our dedicated page for Castle Biosciences news (Ticker: CSTL), a resource for investors and traders seeking the latest updates and insights on Castle Biosciences stock.
Castle Biosciences, Inc. develops and commercializes molecular diagnostic tests used to guide care in dermatologic and gastroenterological disease. Its recurring updates focus on test report volume, revenue performance, guidance, and clinical evidence for products such as DecisionDx-Melanoma and TissueCypher.
Company news also covers studies, publications, and medical-meeting presentations involving risk stratification for cutaneous melanoma, sentinel lymph node biopsy decision support through DecisionDx-Melanoma’s i31-SLNB result, and Barrett’s esophagus progression-risk assessment with TissueCypher. Financial releases frequently discuss core revenue drivers, reimbursement effects, commercial focus, and quarterly operating results.
Castle Biosciences (Nasdaq: CSTL) announced a December 12, 2025 systematic review and meta-analysis in Journal of Clinical Gastroenterology showing the TissueCypher Barrett’s Esophagus test provides validated risk stratification versus pathology or clinical factors alone.
The SRMA pooled six published studies and found high-risk TissueCypher results were 6.7x more likely to progress to high-grade dysplasia or esophageal adenocarcinoma within five years (p<0.0001). Annual progression rates were 5.6% for high-risk and 2.8% for high/intermediate-risk, both above a 1.7% LGD benchmark.
Castle Biosciences (Nasdaq: CSTL) announced an independent expert consensus paper published Dec 9, 2025 endorsing DecisionDx-Melanoma as a best-practice prognostic tool for cutaneous melanoma.
The paper—authored by ten melanoma experts after reviewing 26 studies covering >7,500 patients—reached unanimous agreement on nine statements: DecisionDx-Melanoma provides prognostic information independent of clinicopathologic factors, complements AJCC8 staging, guides sentinel lymph node biopsy (SLNB) decisions in T1b–T3 tumors, informs management of SLNB-negative patients, and is associated with improved melanoma-specific and overall survival versus untested patients.
Castle Biosciences (Nasdaq: CSTL) announced it was named a Houston Chronicle Top Workplace on Nov 17, 2025, marking the fifth consecutive year the company has earned the Houston metro designation.
Castle also received three national Top Workplaces Culture Excellence awards for Employee Appreciation, Employee Well-Being and Professional Development. The company said it has more than doubled its workforce since first earning the Top Workplaces recognition in 2021 and received a total of 13 Top Workplaces awards so far in 2025, including Top Workplaces USA and industry- and regional recognitions.
Castle Biosciences (Nasdaq: CSTL) reported new data showing its DecisionDx-Melanoma test improves sentinel lymph node biopsy (SLNB) decision-making and recurrence risk prediction in cutaneous melanoma. Two oral presentations will occur at ECDO on Nov 17–18, 2025.
The i31-SLNB algorithm outperformed the MIA nomogram (AUC=0.74 vs. 0.61; p=0.001), identifying a 2.6% actual SLN positivity rate for patients predicted 5% risk versus by MIA. In a multicenter study of 810 SLN-negative patients, the 31-GEP independently predicted poorer five-year outcomes (Class 2B vs others; p<0.001) and improved prognostic accuracy when added to AJCC staging (ANOVA χ²=7.75, p=0.02).
Castle Biosciences (NASDAQ: CSTL) said its executive management will present a company overview at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, Dec. 2, 2025 at 1:10 p.m. ET. A live audio webcast will be available at the company’s investor events page and a replay will be posted after the live broadcast.
Castle Biosciences (Nasdaq: CSTL) reported Q3 2025 revenue of $83.0 million and delivered 26,841 total test reports. The company raised full‑year 2025 revenue guidance to $327–335 million from $310–320 million and launched AdvanceAD‑Tx, a 487‑gene expression test for systemic treatment decisions in moderate‑to‑severe atopic dermatitis (ages 12+).
Core test volumes grew: DecisionDx‑Melanoma 10,459 and TissueCypher 10,609 reports in Q3; core revenue drivers test reports increased 36% year‑over‑year. The Novitas LCD excluding DecisionDx‑SCC (effective April 24, 2025) and discontinuation of IDgenetix affected revenue and volumes.
Castle Biosciences (Nasdaq: CSTL) launched AdvanceAD-Tx on November 3, 2025, a 487-gene expression profile test to guide systemic treatment choice for patients aged 12+ with moderate-to-severe atopic dermatitis.
Validation data showed 30.4% of samples had a JAK inhibitor responder profile; those treated with JAKi reached EASI-90 by three months at 45.5% vs 8.3% (p=0.021), had higher vIGA-AD clear rates (36.4% vs 0%, p=0.006), more “no itch” reports (45.5% vs 8.3%, p=0.021), and remained flare-free more often (54.5% vs 16.7%, p=0.041).
Castle estimates a U.S. TAM of $33 billion, is pursuing reimbursement pathways, and is beginning a measured limited-access commercial launch in November 2025 with phased expansion through 2026.
Castle Biosciences (Nasdaq: CSTL) said its executive management will present a company overview at the Stephens 27th Annual Investment Conference on Nov 19, 2025 at 10:00 a.m. ET. A live audio webcast will be available at the company’s investor website and a replay will be posted after the broadcast. Castle also will be available for one-on-one investor meetings at the Jefferies Global Healthcare Conference on Nov 18–20, 2025, with meetings requestable through Jefferies Financial Group.
Castle Biosciences (Nasdaq: CSTL) presented new data at ACG 2025 showing the TissueCypher test provides risk insights beyond pathology and influenced clinical management in multiple Barrett’s esophagus cohorts.
Key highlights: TissueCypher returned five-year progression probabilities of 34%, 62%, 43% and 45% in case studies, exceeded published HGD→EAC five-year rate of 33%, and influenced management in 93% of 114 rural NDBE patients; three posters were presented, one received a Presidential Poster Award.
Castle Biosciences (Nasdaq: CSTL) announced presentation of validation data showing its DecisionDx-Melanoma test stratified risk across histological subtypes in a real-world cohort of 13,560 stage I–III cutaneous melanoma patients.
Key findings include five-year melanoma-specific survival differences by test class (example: nodular melanoma 98.5% vs 82.3% for Class 1A vs 2B) and higher early distant-metastasis rates in Class 2B (AJCC stage I–II cohort n=1,661; CNS 7.4% vs 0.9%).
Castle also presented prospective, multicenter data (49 U.S. sites) for a 487-gene atopic dermatitis GEP that identifies a JAKi responder profile to guide systemic therapy selection.